N
600812
vs
S
Shanghai Composite
Over the past 12 months, North China Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of -14% compared to the Shanghai Composite's +22% growth.
Stocks Performance
600812 vs Shanghai Composite
Performance Gap
600812 vs Shanghai Composite
Performance By Year
600812 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
North China Pharmaceutical Co Ltd
Glance View
In the heart of China's industrial evolution, North China Pharmaceutical Co., Ltd. (NCPC) has thrived as a prominent player in the global pharmaceutical arena. Established in 1953, NCPC has grown from being a state-owned entity to one of the world's largest antibiotic producers. Nestled within the bustling Shijiazhuang region, the company commands a significant presence in the industry, leveraging its extensive experience and formidable R&D capabilities. The backbone of NCPC's operations lies in its integrated production lines, which link raw materials seamlessly with advanced pharmaceutical synthesis processes. This setup enables the company to efficiently churn out a diverse range of products, from bulk antibiotics like penicillin and streptomycin to high-value biotech and nutritional products. NCPC sustains its financial health through a blend of domestic dominance and robust international outreach, catering to over 100 countries. Its revenue streams are diversified across various segments, including prescription drugs, over-the-counter medication, and nutritional supplements. Central to its business model is the balance between cost-effective mass production and a push towards innovation-driven therapies, aligning with China's broader healthcare reforms. The company's growth is further bolstered by strategic partnerships and continuous improvements in its technological framework, ensuring NCPC remains a key contender in the ever-competitive pharmaceutical landscape. Through these strategies, North China Pharmaceutical not only upholds its legacy but continues to write new chapters in the global pharmaceutical story.
